AstraZeneca’s drug gets nod to treat limited-stage cell lung cancer patients
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US.
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.
Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.
Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.
Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the.